Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
mML - L1 - all population, ... vs. immune chekpoint inhibitors, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results CheckMate 067 (N vs I ; all population), 2015 (REV) 1.59 [1.22; 2.06]
CheckMate 067 (NI vs I ; all population), 2015 (REV) 1.82 [1.39; 2.38]
CheckMate 069 (all population), 2015 (REV) 1.35 [0.79; 2.31]
1.65 [1.39 ; 1.97 ] CheckMate 067 (N vs I ; all population), 2015 (REV), CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV) 3 0% 1,402 low not evaluable deaths (OS) (extension)detailed results CheckMate 067 (N vs I ; all population), 2015 (REV) 1.59 [1.31; 1.92]
CheckMate 067 (NI vs I ; all population), 2015 (REV) 1.92 [1.56; 2.37]
1.74 [1.44 ; 2.10 ] CheckMate 067 (N vs I ; all population), 2015 (REV), CheckMate 067 (NI vs I ; all population), 2015 (REV) 2 43% 1,260 low not evaluable PFS (extension)detailed results CheckMate 067 (N vs I ; all population), 2015 (REV) 1.89 [1.56; 2.28]
CheckMate 067 (NI vs I ; all population), 2015 (REV) 2.38 [1.97; 2.87]
CheckMate 069 (all population), 2015 (REV) 2.78 [1.74; 4.43]
2.21 [1.80 ; 2.70 ] CheckMate 067 (N vs I ; all population), 2015 (REV), CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV) 3 52% 1,402 low not evaluable progression or deaths (PFS)detailed results CheckMate 067 (N vs I ; all population), 2015 (REV) 1.75 [1.32; 2.33]
CheckMate 067 (NI vs I ; all population), 2015 (REV) 2.38 [1.76; 3.23]
CheckMate 069 (all population), 2015 (REV) 2.63 [1.59; 4.36]
2.13 [1.67 ; 2.72 ] CheckMate 067 (N vs I ; all population), 2015 (REV), CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV) 3 32% 1,402 low not evaluable objective responses (ORR)detailed results CheckMate 067 (N vs I ; all population), 2015 (REV) 0.29 [0.17; 0.49]
CheckMate 067 (NI vs I ; all population), 2015 (REV) 0.16 [0.10; 0.28]
CheckMate 069 (all population), 2015 (REV) 0.07 [0.04; 0.12]
0.15 [0.07 ; 0.34 ] CheckMate 067 (N vs I ; all population), 2015 (REV), CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV) 3 84% 1,402 low not evaluable objective responses (ORR) (extension)detailed results CheckMate 067 (N vs I ; all population), 2015 (REV) 0.28 [0.20; 0.41]
CheckMate 067 (NI vs I ; all population), 2015 (REV) 0.16 [0.11; 0.23]
CheckMate 069 (all population), 2015 (REV) 0.08 [0.03; 0.23]
0.18 [0.10 ; 0.31 ] CheckMate 067 (N vs I ; all population), 2015 (REV), CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV) 3 75% 1,402 low not evaluable TRAE (any grade)detailed results CheckMate 067 (N vs I ; all population), 2015 (REV) 0.99 [0.63; 1.56]
CheckMate 067 (NI vs I ; all population), 2015 (REV) 0.27 [0.14; 0.51]
CheckMate 069 (all population), 2015 (REV) 1.33 [0.34; 5.28]
0.66 [0.24 ; 1.82 ] CheckMate 067 (N vs I ; all population), 2015 (REV), CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV) 3 83% 1,388 low not evaluable TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 (REV) 1.40 [0.97; 2.03]
CheckMate 067 (NI vs I ; all population), 2015 (REV) 0.26 [0.19; 0.37]
CheckMate 069 (all population), 2015 (REV) 0.26 [0.12; 0.58]
0.47 [0.13 ; 1.63 ] CheckMate 067 (N vs I ; all population), 2015 (REV), CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV) 3 96% 1,388 low not evaluable TRAE leading to death (grade 5)detailed results CheckMate 067 (N vs I ; all population), 2015 (REV) 1.01 [0.02; 50.88]
CheckMate 067 (NI vs I ; all population), 2015 (REV) 1.01 [0.02; 50.88]
1.01 [0.06 ; 16.13 ] CheckMate 067 (N vs I ; all population), 2015 (REV), CheckMate 067 (NI vs I ; all population), 2015 (REV) 2 0% 1,248 low not evaluable TRAE leading to discontinuation (any grade)detailed results CheckMate 067 (N vs I ; all population), 2015 (REV) 1.40 [0.88; 2.21]
CheckMate 067 (NI vs I ; all population), 2015 (REV) 0.25 [0.17; 0.37]
CheckMate 069 (all population), 2015 (REV) 0.24 [0.10; 0.57]
0.45 [0.13 ; 1.56 ] CheckMate 067 (N vs I ; all population), 2015 (REV), CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV) 3 94% 1,388 low not evaluable TRAE leading to discontinuation (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 (REV) 1.93 [1.14; 3.27]
CheckMate 067 (NI vs I ; all population), 2015 (REV) 0.37 [0.25; 0.55]
CheckMate 069 (all population), 2015 (REV) 0.24 [0.09; 0.63]
0.57 [0.16 ; 2.01 ] CheckMate 067 (N vs I ; all population), 2015 (REV), CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV) 3 93% 1,388 low not evaluable Abdominal pain TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 (REV) 4.05 [0.18; 90.07]
CheckMate 067 (NI vs I ; all population), 2015 (REV) 2.02 [0.18; 22.39]
CheckMate 069 (all population), 2015 (REV) 4.16 [0.14; 126.20]
2.92 [0.56 ; 15.39 ] CheckMate 067 (N vs I ; all population), 2015 (REV), CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV) 3 0% 1,388 low not evaluable Adrenal insufficiency TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 (REV) 0.50 [0.05; 5.56]
CheckMate 067 (NI vs I ; all population), 2015 (REV) 0.17 [0.02; 1.38]
CheckMate 069 (all population), 2015 (REV) 4.23 [0.37; 47.88]
0.66 [0.10 ; 4.29 ] CheckMate 067 (N vs I ; all population), 2015 (REV), CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV) 3 49% 1,388 low not evaluable Arthralgia TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 (REV) 0.50 [0.02; 15.03]
CheckMate 067 (NI vs I ; all population), 2015 (REV) 0.25 [0.01; 5.58]
CheckMate 069 (all population), 2015 (REV) 2.05 [0.04; 105.24]
0.54 [0.07 ; 3.92 ] CheckMate 067 (N vs I ; all population), 2015 (REV), CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV) 3 0% 1,388 low not evaluable Asthenia TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 (REV) 2.02 [0.18; 22.39]
CheckMate 067 (NI vs I ; all population), 2015 (REV) 2.02 [0.18; 22.39]
CheckMate 069 (all population), 2015 (REV) 2.05 [0.04; 105.24]
2.02 [0.42 ; 9.65 ] CheckMate 067 (N vs I ; all population), 2015 (REV), CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV) 3 0% 1,388 low not evaluable Chills TRAE (grade 3-4)detailed results CheckMate 069 (all population), 2015 (REV) 2.05 [0.04; 105.24]
2.05 [0.04 ; 105.24 ] CheckMate 069 (all population), 2015 (REV) 1 0% 140 NA not evaluable Colitis TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 (REV) 8.64 [2.57; 29.01]
CheckMate 067 (NI vs I ; all population), 2015 (REV) 0.92 [0.52; 1.65]
CheckMate 069 (all population), 2015 (REV) 0.34 [0.09; 1.23]
1.38 [0.28 ; 6.68 ] CheckMate 067 (N vs I ; all population), 2015 (REV), CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV) 3 86% 1,388 low not evaluable Constipation TRAE (grade 3-4)detailed results CheckMate 069 (all population), 2015 (REV) 1.02 [0.03; 31.03]
1.02 [0.03 ; 31.03 ] CheckMate 069 (all population), 2015 (REV) 1 0% 140 NA not evaluable Cough TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 (REV) 0.25 [0.01; 5.58]
CheckMate 067 (NI vs I ; all population), 2015 (REV) 1.01 [0.02; 50.88]
0.43 [0.04 ; 4.88 ] CheckMate 067 (N vs I ; all population), 2015 (REV), CheckMate 067 (NI vs I ; all population), 2015 (REV) 2 0% 1,248 low not evaluable Decreased appetite TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 (REV) 2.02 [0.07; 60.32]
CheckMate 067 (NI vs I ; all population), 2015 (REV) 0.25 [0.03; 2.24]
CheckMate 069 (all population), 2015 (REV) 2.05 [0.04; 105.24]
0.60 [0.11 ; 3.21 ] CheckMate 067 (N vs I ; all population), 2015 (REV), CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV) 3 0% 1,388 low not evaluable Diarrhoea TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 (REV) 2.08 [0.92; 4.69]
CheckMate 067 (NI vs I ; all population), 2015 (REV) 0.60 [0.33; 1.11]
CheckMate 069 (all population), 2015 (REV) 1.02 [0.33; 3.19]
1.05 [0.47 ; 2.36 ] CheckMate 067 (N vs I ; all population), 2015 (REV), CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV) 3 65% 1,388 low not evaluable Dry skin TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 (REV) 1.01 [0.02; 50.88]
CheckMate 067 (NI vs I ; all population), 2015 (REV) 0.73 [0.33; 1.61]
0.74 [0.34 ; 1.61 ] CheckMate 067 (N vs I ; all population), 2015 (REV), CheckMate 067 (NI vs I ; all population), 2015 (REV) 2 0% 1,248 low not evaluable Dyspnoea TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 (REV) 0.50 [0.02; 15.03]
CheckMate 067 (NI vs I ; all population), 2015 (REV) 0.17 [0.01; 3.34]
CheckMate 069 (all population), 2015 (REV) 0.33 [0.02; 6.80]
0.29 [0.05 ; 1.76 ] CheckMate 067 (N vs I ; all population), 2015 (REV), CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV) 3 0% 1,388 low not evaluable Endocrine disorders TRAE (grade 3-4) detailed results CheckMate 069 (all population), 2015 (REV) 0.81 [0.15; 4.34]
0.81 [0.15 ; 4.34 ] CheckMate 069 (all population), 2015 (REV) 1 0% 140 NA not evaluable Fatigue TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 (REV) 1.01 [0.20; 5.03]
CheckMate 067 (NI vs I ; all population), 2015 (REV) 0.22 [0.06; 0.80]
CheckMate 069 (all population), 2015 (REV) 0.20 [0.01; 3.66]
0.38 [0.13 ; 1.06 ] CheckMate 067 (N vs I ; all population), 2015 (REV), CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV) 3 12% 1,388 low not evaluable Gastrointestinal disorders TRAE (grade 3-4) detailed results CheckMate 069 (all population), 2015 (REV) 0.45 [0.16; 1.29]
0.45 [0.16 ; 1.29 ] CheckMate 069 (all population), 2015 (REV) 1 0% 140 NA not evaluable Headache TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 (REV) 2.02 [0.07; 60.32]
CheckMate 067 (NI vs I ; all population), 2015 (REV) 0.50 [0.05; 5.56]
CheckMate 069 (all population), 2015 (REV) 0.51 [0.02; 11.44]
0.70 [0.13 ; 3.69 ] CheckMate 067 (N vs I ; all population), 2015 (REV), CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV) 3 0% 1,388 low not evaluable Hepatitis TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 (REV) 1.01 [0.02; 50.88]
CheckMate 067 (NI vs I ; all population), 2015 (REV) 0.10 [0.01; 1.82]
CheckMate 069 (all population), 2015 (REV) 0.33 [0.02; 6.80]
0.26 [0.04 ; 1.66 ] CheckMate 067 (N vs I ; all population), 2015 (REV), CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV) 3 0% 1,388 low not evaluable Hepatobiliary disorders TRAE (grade 3-4) detailed results CheckMate 069 (all population), 2015 (REV) 0.06 [0.00; 1.08]
0.06 [0.00 ; 1.08 ] CheckMate 069 (all population), 2015 (REV) 1 0% 140 NA not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 (REV) 1.01 [0.02; 50.88]
CheckMate 067 (NI vs I ; all population), 2015 (REV) 0.17 [0.01; 3.34]
CheckMate 069 (all population), 2015 (REV) 2.05 [0.04; 105.24]
0.53 [0.07 ; 4.07 ] CheckMate 067 (N vs I ; all population), 2015 (REV), CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV) 3 0% 1,388 low not evaluable Hypophysitis TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 (REV) 5.10 [0.59; 43.89]
CheckMate 067 (NI vs I ; all population), 2015 (REV) 1.01 [0.29; 3.51]
CheckMate 069 (all population), 2015 (REV) 2.09 [0.29; 15.34]
1.63 [0.63 ; 4.22 ] CheckMate 067 (N vs I ; all population), 2015 (REV), CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV) 3 0% 1,388 low not evaluable Hypothyroidism TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 (REV) 1.01 [0.02; 50.88]
CheckMate 067 (NI vs I ; all population), 2015 (REV) 0.50 [0.02; 15.03]
CheckMate 069 (all population), 2015 (REV) 2.05 [0.04; 105.24]
0.94 [0.11 ; 8.10 ] CheckMate 067 (N vs I ; all population), 2015 (REV), CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV) 3 0% 1,388 low not evaluable Increase AST TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 (REV) 0.67 [0.11; 4.03]
CheckMate 067 (NI vs I ; all population), 2015 (REV) 0.10 [0.02; 0.43]
CheckMate 069 (all population), 2015 (REV) 0.14 [0.01; 2.46]
0.21 [0.06 ; 0.74 ] CheckMate 067 (N vs I ; all population), 2015 (REV), CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV) 3 25% 1,388 low not evaluable Increased ALT TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 (REV) 1.26 [0.34; 4.75]
CheckMate 067 (NI vs I ; all population), 2015 (REV) 0.17 [0.07; 0.46]
CheckMate 069 (all population), 2015 (REV) 0.09 [0.01; 1.62]
0.33 [0.07 ; 1.57 ] CheckMate 067 (N vs I ; all population), 2015 (REV), CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV) 3 69% 1,388 low not evaluable Increased lipase level TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 (REV) 0.86 [0.39; 1.88]
CheckMate 067 (NI vs I ; all population), 2015 (REV) 0.33 [0.17; 0.65]
CheckMate 069 (all population), 2015 (REV) 0.24 [0.03; 1.97]
0.47 [0.22 ; 1.02 ] CheckMate 067 (N vs I ; all population), 2015 (REV), CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV) 3 46% 1,388 low not evaluable Maculopapular rash TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 (REV) 0.50 [0.05; 5.56]
CheckMate 067 (NI vs I ; all population), 2015 (REV) 0.17 [0.02; 1.38]
CheckMate 069 (all population), 2015 (REV) 0.33 [0.02; 6.80]
0.28 [0.07 ; 1.15 ] CheckMate 067 (N vs I ; all population), 2015 (REV), CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV) 3 0% 1,388 low not evaluable Myalgia TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 (REV) 0.50 [0.02; 15.03]
CheckMate 067 (NI vs I ; all population), 2015 (REV) 0.50 [0.02; 15.03]
CheckMate 069 (all population), 2015 (REV) 2.05 [0.04; 105.24]
0.74 [0.09 ; 5.73 ] CheckMate 067 (N vs I ; all population), 2015 (REV), CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV) 3 0% 1,388 low not evaluable Nausea TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 (REV) 4.05 [0.18; 90.07]
CheckMate 067 (NI vs I ; all population), 2015 (REV) 0.28 [0.06; 1.37]
CheckMate 069 (all population), 2015 (REV) 2.07 [0.13; 33.80]
0.87 [0.16 ; 4.76 ] CheckMate 067 (N vs I ; all population), 2015 (REV), CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV) 3 35% 1,388 low not evaluable Pneumonitis TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 (REV) 1.01 [0.06; 16.16]
CheckMate 067 (NI vs I ; all population), 2015 (REV) 0.33 [0.03; 3.22]
CheckMate 069 (all population), 2015 (REV) 1.02 [0.09; 11.57]
0.66 [0.16 ; 2.72 ] CheckMate 067 (N vs I ; all population), 2015 (REV), CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV) 3 0% 1,388 low not evaluable Pruritic rash TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 (REV) 1.01 [0.02; 50.88]
CheckMate 067 (NI vs I ; all population), 2015 (REV) 1.01 [0.02; 50.88]
CheckMate 069 (all population), 2015 (REV) 2.05 [0.04; 105.24]
1.28 [0.13 ; 12.32 ] CheckMate 067 (N vs I ; all population), 2015 (REV), CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV) 3 0% 1,388 low not evaluable Pruritus TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 (REV) 1.01 [0.06; 16.16]
CheckMate 067 (NI vs I ; all population), 2015 (REV) 0.17 [0.02; 1.38]
CheckMate 069 (all population), 2015 (REV) 1.02 [0.03; 31.03]
0.40 [0.09 ; 1.83 ] CheckMate 067 (N vs I ; all population), 2015 (REV), CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV) 3 0% 1,388 low not evaluable Pyrexia TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 (REV) 2.02 [0.07; 60.32]
CheckMate 067 (NI vs I ; all population), 2015 (REV) 0.50 [0.05; 5.56]
CheckMate 069 (all population), 2015 (REV) 0.33 [0.02; 6.80]
0.62 [0.12 ; 3.19 ] CheckMate 067 (N vs I ; all population), 2015 (REV), CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV) 3 0% 1,388 low not evaluable Rash TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 (REV) 5.10 [0.59; 43.89]
CheckMate 067 (NI vs I ; all population), 2015 (REV) 0.50 [0.17; 1.47]
CheckMate 069 (all population), 2015 (REV) 0.20 [0.01; 3.66]
0.82 [0.15 ; 4.38 ] CheckMate 067 (N vs I ; all population), 2015 (REV), CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV) 3 54% 1,388 low not evaluable Renal and urinary disorders TRAE (grade 3-4) detailed results CheckMate 069 (all population), 2015 (REV) 1.02 [0.03; 31.03]
1.02 [0.03 ; 31.03 ] CheckMate 069 (all population), 2015 (REV) 1 0% 140 NA not evaluable Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4) detailed results CheckMate 069 (all population), 2015 (REV) 0.67 [0.07; 6.66]
0.67 [0.07 ; 6.66 ] CheckMate 069 (all population), 2015 (REV) 1 0% 140 NA not evaluable Skin and subcutaneous tissue disorders TRAE (grade 3-4) detailed results CheckMate 069 (all population), 2015 (REV) 0.10 [0.01; 1.83]
0.10 [0.01 ; 1.83 ] CheckMate 069 (all population), 2015 (REV) 1 0% 140 NA not evaluable Thyroiditis TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 (REV) 1.01 [0.02; 50.88]
CheckMate 067 (NI vs I ; all population), 2015 (REV) 0.50 [0.02; 15.03]
0.68 [0.05 ; 8.83 ] CheckMate 067 (N vs I ; all population), 2015 (REV), CheckMate 067 (NI vs I ; all population), 2015 (REV) 2 0% 1,248 low not evaluable Vitiligo TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 (REV) 0.50 [0.02; 15.03]
CheckMate 067 (NI vs I ; all population), 2015 (REV) 1.01 [0.02; 50.88]
CheckMate 069 (all population), 2015 (REV) 2.05 [0.04; 105.24]
0.94 [0.11 ; 8.10 ] CheckMate 067 (N vs I ; all population), 2015 (REV), CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV) 3 0% 1,388 low not evaluable Vomiting TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 (REV) 1.01 [0.06; 16.16]
CheckMate 067 (NI vs I ; all population), 2015 (REV) 0.14 [0.02; 1.15]
CheckMate 069 (all population), 2015 (REV) 1.02 [0.03; 31.03]
0.37 [0.08 ; 1.66 ] CheckMate 067 (N vs I ; all population), 2015 (REV), CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV) 3 0% 1,388 low not evaluable Weight decreased TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 (REV) 2.02 [0.07; 60.32]
CheckMate 067 (NI vs I ; all population), 2015 (REV) 2.02 [0.07; 60.32]
2.02 [0.18 ; 22.29 ] CheckMate 067 (N vs I ; all population), 2015 (REV), CheckMate 067 (NI vs I ; all population), 2015 (REV) 2 0% 1,248 low not evaluable 0.0 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-07-05 11:34 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 68
- treatments: 329
